(NASDAQ: RLAY) Relay Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 67.48%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.64%.
Relay Therapeutics's earnings in 2025 is -$297,593,000.On average, 13 Wall Street analysts forecast RLAY's earnings for 2026 to be -$293,140,150, with the lowest RLAY earnings forecast at -$388,970,096, and the highest RLAY earnings forecast at -$243,864,596. On average, 8 Wall Street analysts forecast RLAY's earnings for 2027 to be -$302,014,256, with the lowest RLAY earnings forecast at -$419,544,165, and the highest RLAY earnings forecast at -$236,585,056.
In 2028, RLAY is forecast to generate -$280,504,948 in earnings, with the lowest earnings forecast at -$397,462,893 and the highest earnings forecast at -$174,708,964.